Immunic (NASDAQ:IMUX) Earns "Buy" Rating from HC Wainwright

Key Points

• Immunic's stock has received a "Buy" rating from HC Wainwright, with a target price set at $10.00.
• The company recently reported a quarterly loss of ($0.20) earnings per share, falling short of analysts' estimates by $0.02.
• Institutional ownership stands at about 51.82%, with significant increased stakes from several major investors in recent quarters.

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $10.00 target price on the stock.

Separately, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $8.33.

Immunic Trading Up 2.2%

IMUX stock opened at $0.90 on Friday. The firm has a 50-day moving average of $0.90 and a two-hundred day moving average of $0.92. The company has a market cap of $88.62 million, a price-to-earnings ratio of -0.96 and a beta of 1.44. Immunic has a 12 month low of $0.56 and a 12 month high of $1.73.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, equities analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Aberdeen Group plc increased its stake in shares of Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company's stock worth $5,750,000 after acquiring an additional 7,184,457 shares during the period. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after purchasing an additional 415,104 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares in the last quarter. 683 Capital Management LLC lifted its stake in shares of Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after buying an additional 200,000 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after buying an additional 479,846 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.